Literature DB >> 21625253

An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics.

S J Wolf1, M Bachtiar, J Wang, T S Sim, S S Chong, C G L Lee.   

Abstract

The human ABCB1 protein, (P-glycoprotein or MDR1) is a membrane-bound glycoprotein that harnesses the energy of ATP hydrolysis to drive the unidirectional transport of substrates from the cytoplasm to the extracellular space. As a large range of therapeutic agents are known substrates of ABCB1 protein, its role in the onset of multidrug resistance has been the focus of much research. This role has been of particular interest in the field of pharmacogenomics where genetic variation within the ABCB1 gene, particularly in the form of single nucleotide polymorphisms (SNPs), is believed to contribute to inter-individual variation in ABCB1 function and drug response. In this review we provide an update on the influence of coding region SNPs within the ABCB1 gene on drug pharmacokinetics. By utilizing the crystal structure of the mouse ABCB1 homolog (Abcb1a), which is 87% homologous to the human sequence, we accompany this discussion with a graphical representation of residue location for amino acids corresponding to human ABCB1 coding region SNPs. Also, an assessment of residue conservation, which is calculated following multiple sequence alignment of 11 confirmed sequences of ABCB1 homologs, is presented and discussed. Superimposing a 'heat map' of residue homology to the Abcb1a crystal structure has permitted additional insights into both the conservation of individual residues and the conservation of their immediate surroundings. Such graphical representation of residue location and conservation supplements this update of ABCB1 pharmacogenetics to help clarify the often confounding reports on the influence of ABCB1 polymorphisms on drug pharmacokinetics and response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21625253     DOI: 10.1038/tpj.2011.16

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  26 in total

Review 1.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 2.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

3.  Minimum information required for a DMET experiment reporting.

Authors:  Judit Kumuthini; Mamana Mbiyavanga; Emile R Chimusa; Jyotishman Pathak; Panu Somervuo; Ron Hn Van Schaik; Vita Dolzan; Clint Mizzi; Kusha Kalideen; Raj S Ramesar; Milan Macek; George P Patrinos; Alessio Squassina
Journal:  Pharmacogenomics       Date:  2016-08-22       Impact factor: 2.533

4.  Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects.

Authors:  Lan-Xiang Wu; Chun-Jie Wen; Ying Li; Xue Zhang; Ying-Ying Shao; Zhu Yang; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 5.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

6.  Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

Authors:  Francesco Ceppi; Chloé Langlois-Pelletier; Vincent Gagné; Julie Rousseau; Claire Ciolino; Samanta De Lorenzo; Kojok M Kevin; Diana Cijov; Stephen E Sallan; Lewis B Silverman; Donna Neuberg; Jeffery L Kutok; Daniel Sinnett; Caroline Laverdière; Maja Krajinovic
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

7.  Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males.

Authors:  Lan-Xiang Wu; Hong-Bo Zhao; Chun-Jie Wen; Ying Li; Ying-Ying Shao; Zhu Yang; Hong-Hao Zhou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

8.  Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.

Authors:  Khyati Kapoor; Jaya Bhatnagar; Eduardo E Chufan; Suresh V Ambudkar
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

9.  ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.

Authors:  Mohamed A M Ali; Walaa Ali Elsalakawy
Journal:  Med Oncol       Date:  2014-10-11       Impact factor: 3.064

10.  Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.

Authors:  Phuong Tran; Hee-Doo Yoo; Lien Ngo; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-10       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.